So the reality is BP for all their effort will not garner any substantial sales there so should have little interest in trying to kneecap Anavex.
I remember all the nail biting that went on because BIIB got to market first, x2, then Lilly all for not. Absolutely amazing results after trying to “climb over the wall” instead of “going through the gate”.